A Dubai wellness clinic's testosterone page tends to open with a mirror, not a molecule. Fatigue that coffee no longer touches. A gym session that used to build muscle and now mostly tires you out. A libido that quietly left the room. Then the question that does the actual selling: what if your last blood test came back normal and you are still exhausted. Book a hormone panel, the page suggests, and find out what normal is hiding.
What that page rarely mentions, on any of the seven Dubai-market pages checked for this piece, is that the drug behind that panel result is not an ordinary prescription topped up at will. Testosterone, in the injectable form Dubai most commonly prescribes it. Sustanon, Andriol, Primoteston Depot: brand names sitting on the Ministry of Health and Prevention's own product register, every one of them carrying the same dispensing code most patients have never heard of. CD(B). Semi-controlled. The same tier of the same regulatory system that, on the very same government document, lists Deca-Durabolin under the plain words "Anabolic Steroids."
That is not a scare line. Testosterone is a legitimate, effective medicine for men with a genuine hormone deficiency, and this piece says so plainly further down. But its UAE classification carries real, checkable consequences for how a clinic may prescribe it, none of which show up in the marketing, and that regulatory fact paired with what current clinical guidance requires before diagnosis is where the honest version of this story starts.
A hormone with its own drug class
Open the Ministry of Health and Prevention's own registered-products list and the testosterone brands Dubai clinics inject sit in plain sight. Andriol 40mg, the oral capsule form. Primoteston Depot 100mg and Sterandryl Retard 250mg, both injectable. Sustanon 250mg, the four-ester blend that dominates Dubai's TRT menus. Virormone, sold as both injection and tablet. Every one of them carries the code CD(B). The same list, a few rows down, gives Deca-Durabolin the plain description "Anabolic Steroids" and files it under the identical tier.
CD(B) means semi-controlled, not narcotic, and the distinction is worth holding onto. Dubai Healthcare City Authority's published prescribing policy draws the legal line the marketing never does: a semi-controlled drug is one with genuine medical benefit that, used long-term or in high doses, carries a real risk of habituation, which is a fair clinical description of exogenous testosterone once you read the sections on blood count and fertility below. It sits beneath the true narcotics schedule set out in UAE Federal Law No. 14 of 1995, and a 289-entry traveller narcotics list maintained under that same law contains zero mentions of testosterone, steroid, anabolic or androgen. It is nothing like carrying an opioid across a border. It is, instead, a hormone the UAE has decided needs a documented, checkable prescribing trail.
The two MOHAP lists that confirm this classification are dated 2007 to 2008 and 2014, snapshots of the same registration system rather than a fresh 2026 filing, and no newer product-level list turned up in researching this piece. What has not changed is the legal framework underneath them, Federal Law No. 14 of 1995 and its later amendments, so the classification is reported here as a still-governing fact rather than a freshly re-verified 2026 document.
Other countries draw broadly the same line, in different words. The United States lists testosterone as a Schedule III controlled substance under the Anabolic Steroid Control Act of 2004. The United Kingdom treats it as Class C, Schedule 4 Part II of the Misuse of Drugs Regulations 2001, and selling it without a prescription there carries up to fourteen years in prison. Britain's NHS also tends to withhold treatment until total testosterone falls under roughly 8 nmol/L, a stricter cut-off than the reference floor used further down in this piece, a reminder that "low" is not one fixed number. Three regulators, three vocabularies, the same underlying judgement: this is not a hormone anyone hands out casually.
Who is allowed to write the prescription
What CD(B) status actually changes, day to day, is who may write the prescription and for how long. Dubai Healthcare City's policy sets out three tiers, and none of the seven Dubai-market pages checked mention any of them.
MOHAP CD(B) STATUS
General practitioner
30 days, no refill
- Prescribing limit
- Up to 30 days per prescription, no refill
- What that means
- A GP-run programme legally puts the patient back in a consultation every month
Specialist
30 days plus one refill
- Prescribing limit
- 30 days, plus one refill for a further 30 days
- Within scope
- Must be within the specialist's own scope of specialty
Consultant
30 days plus two refills
- Prescribing limit
- 30 days, plus two refills of 30 additional days each
- The longest gap
- Up to 90 days before the patient must return
Every tier
The same storage and records rule
- Storage
- A steel cabinet with a single locking system
- Records
- Kept for two years from the last refill
- Who cannot prescribe
- Residents and interns are not permitted to prescribe controlled or semi-controlled drugs
A general practitioner can legally prescribe testosterone in Dubai. What a compliant GP cannot do is write it and disappear: the limit is thirty days, with no automatic refill, so a GP-run programme puts the patient back in a consultation every month by design. A specialist within their own scope of practice can write thirty days plus one thirty-day refill without a fresh visit. A consultant can stretch that to thirty days plus two refills, ninety days before the patient is required to return. The same policy sets a lighter storage rule than for true narcotics, a steel cabinet with a single lock rather than the double-locking cabinet those require, and a shorter records requirement, two years from the last refill rather than five.
It is worth being precise about what this policy is. It is Dubai Healthcare City's own published rulebook, one free zone's operating procedure, not a blanket law binding every clinic across the emirate. What it does show clearly is how the underlying federal semi-controlled framework gets applied on a prescription pad. Residents and interns, the same document adds, are not permitted to prescribe controlled or semi-controlled drugs at all, testosterone included.
A consultant can write three months at once. A GP cannot, and the difference is exactly the point.
Two mornings, not one number
None of that regulatory detail matters if the diagnosis underneath it is loose, and this is where the gap between the clinical standard and the Dubai sales pitch is widest.
The Endocrine Society's 2018 clinical practice guideline is unambiguous: a hypogonadism diagnosis needs real symptoms of testosterone deficiency and "unequivocally and consistently low serum total testosterone," measured by fasting morning blood draw on two separate occasions, not one. The guideline's harmonised reference floor sits at 264 ng/dL, or 9.2 nmol/L. The Society's own follow-up statement, published 16 July 2026, restates the two-test rule for a general readership and gives "a common clinical threshold near 300 ng/dL." The two figures are not in conflict. They are the same professional body describing the same low zone three years apart, in a guideline document and a plain-language statement respectively, and the honest approach is to report both rather than pick one and drop the other.
TWO TESTS, NOT ONE
What the guideline requires
Two mornings, not one number
- Testing
- Two separate early-morning, fasting total testosterone measurements
- Threshold
- A reference floor near 264 to 300 ng/dL, plus real symptoms
- Source
- Endocrine Society, 2018 guideline and its 16 July 2026 statement
What one 2026 US study found
12% met the bar
- Study
- University of Michigan, 200 men prescribed testosterone 2020 to 2025
- Guideline-concordant
- Only 12 percent of initial prescriptions met the full diagnostic criteria
- Presented
- ENDO 2026, Chicago, 13 June 2026
The one Dubai page that gets it right
A lab, not a clinic
- Who
- Doctors Clinic Dubai, a diagnostics-lab blog
- What it says
- Two separate morning blood draws showing testosterone below 300 ng/dL before confirming a diagnosis
- The gap
- No Dubai clinic page selling the injections themselves states this rule
Where the free testosterone number matters more than the total is when total testosterone sits near that lower limit, or when a condition alters sex hormone-binding globulin. There, the guideline calls for a proper method, equilibrium dialysis or a validated calculation, specifically not a direct analogue immunoassay, which is the cheaper, less reliable option some panels still run.
Of the Dubai-market pages checked, six of them selling the injections themselves, only one states the two-test rule in plain language, and it is not a clinic selling treatment. It is Doctors Clinic Dubai's own testing-guide blog, which correctly requires "two separate morning blood draws showing testosterone below 300 ng/dL before confirming a diagnosis," and adds the reason morning timing matters: afternoon testing can run 20 to 30 per cent lower, so a same-day, later appointment can manufacture a false positive on its own. The clinics actually selling the treatment, the ones with a financial reason to welcome a positive result, are the ones silent on how many tests that result needs to survive.
One low number on a symptom quiz is not a diagnosis. Two mornings of blood work is closer to it.
What actually happens in practice: twelve per cent
Real-world prescribing rarely clears that two-test bar, and the best current evidence of how rarely comes from the United States, not Dubai, so this piece reports it as US evidence rather than borrowing a foreign statistic and quietly presenting it as local.
A University of Michigan study presented at ENDO 2026 in Chicago on 13 June 2026 followed two hundred US men, mean age 52.5, prescribed testosterone between 2020 and 2025. Only 12 per cent of the initial prescriptions met full guideline-concordant diagnostic criteria: two low morning readings, LH and FSH measured, no contraindications present. Sixty-two per cent of the cohort had a PSA test beforehand, seventy-seven per cent had a complete blood count, and fifty-five per cent had obstructive sleep apnoea, itself one of the guideline's own reasons not to start treatment. Primary care physicians wrote 45 per cent of the prescriptions, urologists 35.5 per cent, endocrinologists 18 per cent. "Our study findings highlight opportunities to improve patient care and reduce inappropriate testosterone prescribing," said senior author Maria Papaleontiou, associate professor at the University of Michigan.
This is US data, a single academic centre, two hundred patients, and it should never be read as a Dubai statistic. It is, though, the newest and most rigorous number available anywhere on exactly this pattern, in a self-referred, symptom-led population that maps closely onto how Dubai's own wellness clinics court new patients.
When it is the right medicine
None of this is an argument against testosterone therapy. For a man who genuinely meets the diagnostic bar above, confirmed hypogonadism rather than a low-normal number chalked up to age or weight, the Endocrine Society's own guideline recommends treatment on the strength of real, measured improvement in sexual function, mood and elements of physical function. The word doing the work in that sentence is confirmed. Efficacy evidence for men whose testosterone sits merely low-normal, or whose fatigue and low libido have other, unrelated causes, is thinner and less consistent, which is exactly why the two-test rule and the exclusion of low-normal numbers is not bureaucratic caution. It is the difference between a treatment that reliably helps and one that reliably does not, dressed in the same syringe.
The heart question, and the trial that actually answered it
The single fear that has followed testosterone therapy for two decades is cardiovascular: does raising an older man's testosterone raise his risk of a heart attack or stroke. The best current answer comes from the TRAVERSE trial, a randomised, placebo-controlled trial run specifically to test that question, published in the New England Journal of Medicine in June 2023. Worth flagging upfront: the secondary-endpoint percentages below come from clinical summaries of the trial, cross-checked across independent clinical sources, rather than a direct read of the paywalled primary paper.
The trial enrolled 5,246 men aged 45 to 80 with confirmed hypogonadism symptoms and either documented cardiovascular disease or a high cardiovascular risk profile, and randomised them to a daily transdermal 1.62 per cent testosterone gel or a placebo gel. On the primary endpoint, major adverse cardiovascular events, testosterone was noninferior to placebo over one to four years of follow-up. The Endocrine Society's own July 2026 statement summarises the finding plainly: "no meaningful increase in heart attack and stroke."
That reassurance is real and worth reporting as such rather than burying under caveats. It is not, though, a blanket safety clearance. The trial's secondary findings showed higher rates of atrial fibrillation with testosterone, 3.5 per cent against 2.4 per cent on placebo, and acute kidney injury, 2.3 per cent against 1.5 per cent, both statistically significant. Pulmonary embolism ran higher too, 0.9 per cent against 0.5 per cent, which the Endocrine Society's statement rounds to roughly a 50 per cent relative increase, and the trial recorded more bone fractures in the testosterone group as well. And the trial was run on a gel, not an injection, the delivery route Dubai's own clinics most commonly sell, which matters more than it sounds once blood count enters the picture below.
Even the Endocrine Society is careful not to oversell its own reassuring headline. Its statement adds that "long-term safety, including for prostate cancer, remains unestablished," because even a trial of over five thousand men running up to four years may still be too short to catch a slow-developing risk, and the Society is now calling for a long-term "Men's Health Initiative," modelled on the Women's Health Initiative, to close that gap properly.
Thicker blood, and the route that makes it more likely
Testosterone's most common measurable side effect is not the one that makes headlines. It is polycythaemia, a rise in red blood cell count thick enough to raise clotting risk, and a Canadian Urological Association Journal study gives real numbers, by delivery route, that no Dubai clinic page checked names.
THE REAL RISK ROUTE MATTERS
The study followed sixty men, thirty on intranasal testosterone gel and thirty on intramuscular testosterone cypionate injection, and found haematocrit at or above 54 per cent, the guideline's own threshold for a significant adverse event, in three of the thirty injection patients and none of the thirty on the intranasal route. At the lower threshold of 50 per cent, ten of thirty injection patients crossed it against none on intranasal. After adjusting for age, body mass, smoking history and follow-up testosterone level, the injection route on its own still added an average 3.24 percentage points to haematocrit compared with intranasal, a statistically significant, independent effect. A broader systematic review cited within the same paper found a rise in haematocrit was the single most frequent adverse effect of testosterone therapy across the wider literature.
The management rule the paper quotes from the Endocrine Society is unambiguous: a haematocrit above 50 per cent should be a reason not to start treatment, and above 54 per cent a reason to stop it until it comes back down, either by pausing the dose or by therapeutic phlebotomy, blood donation by another name. One limitation worth flagging honestly: the injection group in this study skewed considerably older, 54.9 years on average against 36.6 for the intranasal group, and the researchers adjusted for that in their statistical model rather than ignoring it, but age remains a real factor sitting alongside route.
Of the Dubai pages checked, only Urologic Health Dubai gets close to naming this monitoring requirement at all, promising to track "red blood cells, PSA, and metabolic profiles." Every other treatment-selling page checked offers "regular blood tests" without saying which test, or what number should end the conversation.
The fertility question almost nobody raises
There is a second, quieter effect that matters enormously to a specific slice of Bellora's own readership, men in their thirties and forties who may still want children, and it is close to absent from Dubai's TRT marketing.
Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis: the brain reads the extra hormone in the bloodstream and cuts its own signal, luteinising hormone and follicle-stimulating hormone, that normally drives the testes to produce both testosterone and sperm. A 2022 clinical review puts the mechanism plainly: spermatogenesis meaningfully declines once intratesticular testosterone falls more than 80 per cent below normal, and a course of TRT routinely does exactly that.
It is reversible for most men, but not quickly.
REVERSIBLE, BUT NOT QUICK
A meta-analysis of thirty trials cited in the same review found 67 per cent of men back to at least twenty million sperm per millilitre within six months of stopping, 90 per cent within twelve months, and effectively all of them by twenty-four. A separate cited study found 70 per cent reached more than five million motile sperm per millilitre within a year. Recovery after bodybuilding-dose anabolic steroid use, a heavier and different exposure than medical TRT, ran slower in a separate cited study, averaging just over ten months and ranging from four months to nearly two years depending on prior dose and duration.
For men who want to preserve fertility while treating a genuine deficiency, the same review names two real alternatives clinicians use: low-dose hCG alongside testosterone, which preserved semen parameters in a small retrospective series, and enclomiphene citrate, a non-testosterone option that raises the body's own hormone signal instead of replacing it, with early proof-of-concept results restoring sperm production within six months.
MOHAP's own 2019 public warning about unlicensed hormone and steroid use independently corroborates the mechanism in plain consumer language, describing "disruption and atrophy of the glands producing these hormones, especially male hormone (testosterone) which causes erectile dysfunction (ED) and infertility." Of the Dubai pages checked, only Urologic Health Dubai raises the point plainly, stating that a doctor will prescribe hCG or Clomiphene Citrate for a patient who wants to maintain fertility. No other treatment-selling page checked mentions it at all.
The monthly figure on the menu and the annual figure in your bank statement are rarely the same conversation.
The money, and the number that rarely gets printed
Pricing is where Dubai's TRT market gets genuinely inconsistent, priced by the injection on one page, by the month on another, by a bundled programme on a third, which makes comparing two clinics' "from" figures close to meaningless without reading the fine print underneath.
AS PUBLISHED, PER MONTH
Read those monthly figures carefully: at least two are programme or monitoring fees with the medication billed separately, understating what a patient eventually pays. The clearer number to budget against is the annual figure. Urologic Health Dubai's own published cost guide puts a lean, injection-only year at roughly AED 18,000 to 20,000, and a fully bundled specialist programme, testing, injections and follow-up together, as high as AED 30,000.
THE NUMBER MOST PAGES SKIP
The published annual range
AED 18,000-30,000 a year
- Lean, injections only
- About AED 18,000 to 20,000
- Fully bundled programme
- Up to AED 30,000
- Source
- Urologic Health Dubai's own published cost guide
Usually not in the monthly number
What comes later
- Medication
- Priced separately from the programme fee on at least two Dubai pages checked
- Monitoring bloodwork
- Haematocrit and PSA, required by the clinical guideline, rarely itemised
- VAT
- No Dubai page checked states whether its figure includes 5 percent VAT
The lifelong point
Said plainly by two pages, silent on the rest
- Stated
- "TRT doesn't cure low testosterone. It manages it... for most men it's long-term" - a Dubai cost-guide page
- Also stated
- "TRT is typically a lifelong commitment" - a specialist-positioned Dubai provider
- Not stated
- Every page that actually sells the injection programme, checked in this research
That figure sits inside a wider honesty gap that deserves a precise description, not a sweeping one. Two of the seven Dubai-market pages checked, Urologic Health Dubai's cost-guide article and Metabolic Health, state the lifelong nature of the treatment in almost identical terms. "TRT doesn't cure low testosterone. It manages it... for most men it's long-term," says one. "TRT is typically a lifelong commitment, as testosterone levels naturally decline with age," says the other, which also positions itself explicitly against "wellness models" rather than as one. That is a real, checkable disclosure, and it would be inaccurate to claim no Dubai page makes it. What is accurate is that the disclosure is inconsistent, and it is specifically the pages actually selling the injections, Hortman, Glamorous, Excellage, that stay silent on the question, while The Nova Clinic answers it without really answering it, saying duration "depends on your treatment goals... and hormonal response curve."
The rebound point behind that lifelong language is straightforward. TRT treats the symptom, not the underlying cause, so a body that has supplemented externally for months or years typically has not restarted its own production, and testosterone returns to roughly its pre-treatment level once stopped.
None of the seven pages state whether their published AED figures include the UAE's 5 per cent VAT, and this piece cannot resolve that either, so treat every published figure as potentially excluding it until a clinic confirms otherwise in writing.
Before any of that, the cheapest, lowest-commitment step is simply confirming whether a genuine deficiency exists at all. Doctors Clinic Dubai prices a single testosterone test from AED 200, a fuller male hormone panel from AED 750, and a comprehensive men's health panel, hormones, metabolic markers and vitamins together, from AED 1,500, a fraction of even the cheapest monthly treatment tier above.
Who should not start, and what should be checked once you are on it
The Endocrine Society's guideline sets out a specific list of men who should be advised against starting testosterone at all: those with breast or prostate cancer, a palpable prostate nodule, a PSA above 4 ng/mL, or above 3 ng/mL for men at higher risk including those of African heritage or with a family history; men with an already elevated haematocrit; untreated severe obstructive sleep apnoea; severe lower urinary tract symptoms; uncontrolled heart failure; a heart attack or stroke within the past six months; a clotting disorder; or a near-term wish to have children.
Measured against that list, Dubai's own pages vary sharply. Hortman Clinics publishes a genuinely near-complete set, prostate disease, sleep apnoea, heart failure, blood clots. Metabolic Health names real risks, elevated red blood cells, acne, aggression, prostate enlargement, sleep apnoea, but frames every one of them as a side effect to monitor rather than a reason not to start. Excellage and The Nova Clinic state no contraindications at all on the pages checked.
The monitoring schedule the guideline requires once treatment starts is specific too: a digital rectal exam and PSA test at baseline, repeated three to twelve months in, with a referral to a urologist if PSA rises more than 1.4 ng/mL above that baseline, alongside the haematocrit checks already covered above. Of the pages checked, only Urologic Health Dubai comes close to naming any of this in full. The rest promise regular blood tests without saying for what.
Common questions
Is testosterone a controlled drug in the UAE?
Semi-controlled, CD(B) in MOHAP's own registration system, which sits below true narcotics but above an ordinary prescription. It carries real rules on who can prescribe it, how it is stored, and how long records are kept.
Can a GP prescribe TRT in Dubai, or do I need a specialist?
A GP can, but only in strict thirty-day blocks with no automatic refill. A specialist can add one thirty-day refill without a new visit, and a consultant two, so the tier of doctor changes how often you are required back in the room.
How is low testosterone actually diagnosed?
Two separate early-morning, fasting blood tests below the reference range, plus real symptoms, per the Endocrine Society's own guideline. A single test, or an afternoon draw, is not enough to confirm the diagnosis on its own.
What counts as low, exactly?
Roughly 264 to 300 ng/dL depending on which Endocrine Society document is cited, both describing the same clinical zone rather than disagreeing. The NHS in the UK sets a stricter cut-off nearer 8 nmol/L, about 231 ng/dL, a reminder the number is not fixed everywhere.
Is TRT safe for the heart?
The best current trial, TRAVERSE, found no meaningful rise in heart attack or stroke risk, on a testosterone gel. It did find higher rates of atrial fibrillation, kidney injury and blood clots, and its authors say long-term safety, including for prostate cancer, is still not fully established.
Does TRT raise red blood cell count?
Yes, and the route matters. Injectable testosterone showed a materially higher polycythaemia rate than intranasal gel in one fetched comparison study, and a haematocrit above 54 per cent is treated as a reason to pause treatment.
Does testosterone therapy affect fertility?
Yes. It suppresses the body's own hormone signal to the testes and can meaningfully reduce sperm production. It is usually reversible within six to twenty-four months of stopping, and hCG or enclomiphene are real alternatives for men who want to preserve fertility while treating a genuine deficiency.
Once you start, do you have to stay on it for life?
For most men, yes, and two of the Dubai pages checked for this piece say so directly. TRT manages the level rather than curing the underlying deficiency, so stopping generally means the number returns to where it started.
Does insurance cover TRT in Dubai?
Usually not, unless a clear hypogonadism diagnosis with proper blood-test backing exists, according to one Dubai clinic's own published guidance. Treat it as a self-pay treatment unless your insurer confirms otherwise in writing.
How much does a genuine year of TRT cost in Dubai?
Roughly AED 18,000 to AED 30,000 a year on the two Dubai pages that publish a real annual figure, covering testing, injections and follow-up, before accounting for VAT, which no page checked states either way.
Sources and methodology
This piece draws its regulatory claims from MOHAP's own registered-products lists and Dubai Healthcare City's published prescribing policy, its diagnostic and safety claims from the Endocrine Society's guideline and 2026 statement, the TRAVERSE trial and two further peer-reviewed studies on blood count and fertility, and its pricing from seven Dubai-market clinic and diagnostics pages read directly and attributed by name rather than blended into an average. Where a figure rests on a secondary clinical summary rather than a primary paper, as with several of TRAVERSE's percentages, that is stated at the point it is used. We review this article periodically and update it as policy, guidance or pricing changes.
This is informational and is not individual medical advice. Confirm your own diagnosis, dosing and monitoring plan with a licensed endocrinologist, urologist or andrologist.
- List of Restricted and Controlled Drugs CD(A), 2007-2008, UAE Ministry of Health, Drug Control Department
- List of Controlled Products, Registered and Priced, as of 7 July 2014, MOH UAE Drug Department
- Narcotic, Controlled & Semi-controlled Medications Management Policy (PP/PH/005/01), Dubai Healthcare City Authority
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline, Journal of Clinical Endocrinology & Metabolism, 2018
- Statement on Testosterone Replacement Therapy, Endocrine Society, 16 July 2026
- Testosterone therapy in men may be overprescribed, inconsistent with clinical guidelines, Endocrine Society, ENDO 2026 press release
- Cardiovascular Safety of Testosterone-Replacement Therapy, New England Journal of Medicine, 2023 (the TRAVERSE trial)
- A cross-sectional comparison of secondary polycythemia in testosterone-deficient men treated with nasal testosterone gel vs. intramuscular testosterone cypionate, Canadian Urological Association Journal, 2020
- Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy and anabolic-androgenic steroids, PMC, 2022
- Ministry of Health and Prevention Warns of Promoting and Selling Banned Steroids, MOHAP, 2019
Clinics in our directory include Hortman Clinics on Sheikh Zayed Road, which publishes a monthly TRT price among its listed services, and DNA Health & Wellness in Al Manara, which lists hormonal optimisation among its wellness programmes. For related reading, see our pieces on IV drip therapy in Dubai and weight-loss injections in Dubai, or browse the wider wellness and IV therapy category in our clinic directory.